Efficacy And Safety Of The Anti-Epidermal Growth Factor Antibody (EGFR) IMC-C225, In Combination With Cisplatin In Patients With Recurrent Squamous Cell Carcinoma Of The Head And Neck (SCCHN) Refractory To Cisplatin Containing Chemotherapy

Diana Stripp, MD

University of Pennsylvania Cancer
Ultima Vez Modificado: 13 de mayo del 2001

Translation for this article does not exist